Skip to content

Randomised, controlled, open label, cross-over trial to evaluate the tolerance of a new paediatric sip feed in children in need of oral nutritional support.

Randomised, controlled, open label, cross-over trial to evaluate the tolerance of a new paediatric sip feed in children in need of oral nutritional support.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26666
Enrollment
28
Registered
2010-05-27
Start date
2010-05-18
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children in need of oral nutritional support

Interventions

Test-product: A new paediatric sip feed that is nutritionally complete and energy dense (1.5 kcal/ml). Amount: As pre-scribed by Health Care Professional. Control-product: A standard fibre-enriched p

Sponsors

Danone Research – Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female subjects, aged 3-12 years (including 3 and 12 years) in need of oral nutritional support (subject can be current or new paediatric sip feed user); 2. Subject requires a paediatric sip feed for at least 6 weeks; 3. Both hospitalized subjects and out-patients; 4. Stable health status and expected to remain stable throughout the study (in the opinion of the Health Care Professional); 5. Written informed consent from parents/guardian and subject (if applicable according to local law).

Exclusion criteria

Exclusion criteria: 1. Cow’s milk allergy, known inflammatory bowel diseases, bowel resection; 2. Subjects requiring a fibre-free diet; 3. Known allergy for fruit (apple, pear, strawberry, raspberry, banana, apricot, lemon) and/or carrot; 4. Subjects requiring an adult rather than a paediatric sip feed; 5. Major renal dysfunction (if requiring, but not yet receiving, dialysis); 6. Major hepatic dysfunction (e.g. hepatitis, congenital abnormalities affecting the liver); 7. Major gastrointestinal intolerance (e.g. vomiting, diarrhoea); 8. Inherited metabolic disorders, including galactosaemia; 9. Use of parenteral feeding and/or enteral tube-feeding; 10. Investigator's uncertainty about the willingness or ability of the child/carer to comply with the protocol requirements; 11. Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frame
Tolerance: Daily stool frequency (with diary) and frequency and intensity of gastro-intestinal symptoms (with questionnaire).

Secondary

MeasureTime frame
1. Product appreciation: Overall liking and product evaluation carer (both with questionnaire); 2. Daily study product intake (with diary).

Contacts

Public ContactHeidi Sonnemans

PO box 7005

heidi.sonnemans@danone.com+31 (0)317 467800

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)